61921-33-3

Basic information

• Product Name: TRANS-4-NITROCINNAMOYL CHLORIDE
• Synonyms: TRANS-4-NITROCINNAMOYL CHLORIDE;(2E)-3-(4-nitrophenyl)acryloyl chloride;2-propenoyl chloride, 3-(4-nitrophenyl)-, (2E)-;(E)-3-(4-nitrophenyl)acryloyl chloride;trans-4-Nitrocinnamoyl chloride 97%;3-(4-nitrophenyl)acryloyl chloride
• CAS NO: 61921-33-3
• Molecular Formula: C₉H₆ClNO₃
• Molecular Weight: 211.6
• Product Categories: Acid Halides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 61921-33-3.mol
• Article Data: 80

Chemical Properties

• Melting Point: 150-153 °C(lit.)
• Boiling Point: 319.6°C at 760 mmHg
• Flash Point: 147.1°C
• Appearance: /
• Density: 1.403g/cm³
• Vapor Pressure: 0.000336mmHg at 25°C
• Refractive Index: 1.628
• CAS DataBase Reference: TRANS-4-NITROCINNAMOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: TRANS-4-NITROCINNAMOYL CHLORIDE(61921-33-3)
• EPA Substance Registry System: TRANS-4-NITROCINNAMOYL CHLORIDE(61921-33-3)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3261 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 61921-33-3(Hazardous Substances Data)

Usage

Uses

trans-4-Nitrocinnamoyl chloride may be used as derivatization reagent for the analysis of perhexiline and its monohydroxy metabolite in plasma by HPLC. It may be used as derivatization reagent to investigate the in vitro enzyme kinetics and CYP isoform selectivity of perhexiline monohydroxylation using human liver microsomes.

InChI:InChI=1/C9H6ClNO3/c10-9(12)6-3-7-1-4-8(5-2-7)11(13)14/h1-6H/b6-3+

Upstream product

• 555-16-8 4-nitrobenzaldehdye 
• 882-06-4 4-nitro-trans-cinnamic acid 
• 619-89-6 p-nitrocinnamic acid 

Downstream Products

• 13546-94-6 4-nitro-trans-cinnamic acid-(4-hydroxy-phenyl ester) 
• 105625-82-9 3-[(E)-3-(4-Nitro-phenyl)-acryloyl]-2-phenyl-5-[1-phenyl-meth-(E)-ylidene]-3,5-dihydro-imidazol-4-one 
• 330679-86-2 (E)-N-(4-nitrocinnamoyl)-L-glutamine 
• 286930-76-5 N-(4-nitrocinnamoyl)-2-hydroxy-2-trifluoromethyl-(3,4-methylenedioxyphenyl)ethylamine 
• 13546-97-9 4-nitro-trans-cinnamic acid-(4-dimethylamino-phenyl ester) 
• 351027-13-9 N-(p-nitrocinnamoyl)imidazole 
• 212690-57-8 (E)-1-((1S,5R,7R)-10,10-Dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]dec-4-yl)-3-(4-nitro-phenyl)-propenone 
• 186249-47-8 3,4-dihydro-5-cyano-6-methyl-4-(p-nitrophenyl)-2(1H)-pyridone 
• 173909-85-8 (E)-N-[3-(4-nitrophenyl)acryloyl]benzamide 
• 637-57-0 methyl 4-nitrocinnamate 

Relevant articles and documents

Radiosensitization of human pancreatic cancer by piperlongumine analogues

Radiotherapy is commonly used to treat advanced pancreatic cancers and can improve survival by 2 months in combination with gemcitabine. However, prognosis and survival improvement remain unsatisfactory, and effective therapies are urgently needed. Piperlongumine has been demonstrated to have therapeutic potentials against various cancers. In this study, we synthesized a series of piperlongumine derivatives and provided evidence that piperlongumine derivatives could be used as effective radiosensitizers in pancreatic cancer. Two compounds enhanced the radiosensitivity of Panc-1 and SW1990 cells. In a pancreatic bi-flank xenograft tumor model, they significantly inhibited tumor growth. Piperlongumine derivatives could induce reactive oxygen species (ROS) expression and regulate the Keap1-Nrf2 protective pathway with enhancement of radiation-induced DNA damage, G2/M-phase cell cycle arrest, and apoptosis. Collectively, our data offer a proof of concept for the use of piperlongumine derivatives as a novel class of radiosensitizers for the treatment of pancreatic cancer.

Cinnamyl-containing rupestonic acid methyl ester derivative as well as preparation method and application of rupestonic acid methyl ester derivative

The invention relates to a cinnamyl-containing rupestonic acid methyl ester derivative as well as a preparation method and application thereof, the derivative is prepared by the following steps: reacting rupestonic acid with dimethyl sulfate to obtain rupestonic acid methyl ester, and then obtaining 2-hydroxyl rupestonic acid methyl ester under the oxidation of camphor sulfonyl acridine. and then reacting with cinnamyl chloride under the catalysis of DMAP to obtain 20 rupestonic acid methyl ester derivatives containing cinnamyl groups. The method has the advantages of mild reaction conditions and simple experimental steps. The obtained 1d-20d rupestonic acid methyl ester derivatives containing the cinnamyl groups are subjected to a preliminary in-vitro anti-influenza A H3N2 virus activity test. Experimental results show that the compounds show good activity in 7d, 15d and 18d, and can be used as drugs for resisting influenza A H3N2 virus.

Practical access to fluorescent 2,3-naphthalimide derivatives: Via didehydro-Diels-Alder reaction

A practical and efficient approach for the synthesis of fluorescent 2,3-naphthalimide derivatives has been developed from readily available starting materials via an intramolecular didehydro-Diels-Alder reaction, which proceeded well under room temperature, exhibiting a wide substrate scope and good functional group tolerance. The practicability of this methodology has been verified by one-step synthesis of the environmentally sensitive fluorophore 6-DMN on a gram scale with a shorter time, fewer steps and less waste disposal, and without the utilization of toxic transition metals. The present experimental and computational studies support the crucial role of the propiolimide moiety in the transformation.